This reduction of GLT-1 expression in astrocytes results in increased glutamate levels at the synapse, which, by acting on eNMDAR, contributes to the progression of AD pathology in the human brain (Simpson et al., 2010). Here, SLC1A2 is linked to Alzheimer disease.